SynAct Pharma’s board and management extend lock-up agreements

SynAct Pharma AB (“SynAct”) today announced that all members of its board and management have signed lock-up agreements for their shares in the company until June 30, 2022. In total the lock-up agreements correspond to more than 20 percent of the votes and capital in SynAct Pharma.

The members of the board and management who have joined during the second half of 2021 have entered into new agreements whereas the others have extended their already existing lock-ups for a period of 6 months from the end of this year until end of June 2022. The lock-up prevents the selling of shares, except what is reasonably needed to cover tax payments applicable for Danish holding companies.

“The members of the board and the entire management team reconfirms their commitments to the future development of the company and have no intention of selling their shares now,” said Jeppe Øvlesen, CEO of SynAct Pharma.

The information was submitted, through the agency of the contact person below, for publication on December 7, 2021.

For further information about SynAct Pharma AB, please contact:  

Jeppe Øvlesen                                    
CEO, SynAct Pharma AB                    
Phone: +45 28 44 75 67                       
Mail: joo@synactpharma.com           

Thomas Jonassen
CSO, SynAct Pharma AB
Phone: +45 40 15 66 69
Mail: tj@synactpharma.com

About SynAct Pharma AB 

SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: www.synactpharma.com.